Comparison
BPC-157 vs. Ipamorelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Healing
Growth
CAS no.
137525-51-0
170851-70-4
Molecular weight
1419.5 g/mol
711.86 g/mol
Half-life
4 h
2 h
Sequence
GEPPPGKPADDAGLVAib-His-D-2-Nal-D-Phe-Lys-NH2Mechanism of action
BPC-157
Synthetic peptide derived from a sequence of a protein found in gastric juice. In preclinical models, an influence on angiogenic and tissue-protective signalling pathways has been described. The precise molecular mechanisms of action are not conclusively understood.
Ipamorelin
Ipamorelin is a selective agonist at the GH secretagogue receptor (GHSR-1a). Compared to GHRP-2 and GHRP-6 its selectivity for the growth-hormone axis is higher; ACTH, cortisol and prolactin are not significantly stimulated in clinical studies. This selectivity was the main reason for its development over older GHRPs.
Evidence base
Highest evidence
Animal model
Human RCT
Studies
4
4
of which in humans
0
3
Effects recorded
4
3
Open conflicts
2
1
Documented adverse events
2
1